Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of “Buy” from Analysts

Inozyme Pharma, Inc. (NASDAQ:INZY) has been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $17.00.

Several research analysts have commented on the stock. Wedbush reissued an “outperform” rating and set a $12.00 price objective (down previously from $15.00) on shares of Inozyme Pharma in a report on Tuesday, November 5th. Raymond James started coverage on Inozyme Pharma in a research report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Stifel Nicolaus initiated coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, November 6th.

Hedge Funds Weigh In On Inozyme Pharma

Institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. Series C acquired a new stake in shares of Inozyme Pharma during the second quarter worth $52,000. Virtu Financial LLC acquired a new stake in Inozyme Pharma during the third quarter worth about $64,000. Meeder Asset Management Inc. purchased a new position in Inozyme Pharma during the second quarter valued at approximately $68,000. SG Americas Securities LLC purchased a new position in Inozyme Pharma during the third quarter valued at approximately $81,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Inozyme Pharma in the second quarter valued at approximately $84,000. 88.30% of the stock is owned by hedge funds and other institutional investors.

Inozyme Pharma Trading Down 0.7 %

Shares of Inozyme Pharma stock opened at $2.80 on Friday. Inozyme Pharma has a fifty-two week low of $2.38 and a fifty-two week high of $7.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The company has a market capitalization of $179.87 million, a P/E ratio of -1.79 and a beta of 1.35. The company has a fifty day moving average of $3.09 and a 200 day moving average of $4.41.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. On average, sell-side analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.